ProfileGDS5678 / 1436758_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 74% 72% 66% 72% 75% 66% 72% 70% 71% 72% 73% 68% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6766373
GSM967853U87-EV human glioblastoma xenograft - Control 24.8257174
GSM967854U87-EV human glioblastoma xenograft - Control 34.6313972
GSM967855U87-EV human glioblastoma xenograft - Control 44.0099766
GSM967856U87-EV human glioblastoma xenograft - Control 54.5532572
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8287975
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0602666
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.5622772
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3197770
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.515271
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5603772
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.696273
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2001768
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5662672